103 related articles for article (PubMed ID: 9422083)
21. Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin.
Biliran H; Sheng S
Cancer Res; 2001 Dec; 61(24):8676-82. PubMed ID: 11751384
[TBL] [Abstract][Full Text] [Related]
22. Aberrant glomerular filtration of urokinase-type plasminogen activator in nephrotic syndrome leads to amiloride-sensitive plasminogen activation in urine.
Stæhr M; Buhl KB; Andersen RF; Svenningsen P; Nielsen F; Hinrichs GR; Bistrup C; Jensen BL
Am J Physiol Renal Physiol; 2015 Aug; 309(3):F235-41. PubMed ID: 25972510
[TBL] [Abstract][Full Text] [Related]
23. Tissue plasminogen activator activity in prostatic cancer.
Köller A; Kirchheimer J; Pflüger H; Binder BR
Eur Urol; 1984; 10(6):389-94. PubMed ID: 6085049
[TBL] [Abstract][Full Text] [Related]
24. An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells.
Rabbani SA; Desjardins J; Bell AW; Banville D; Mazar A; Henkin J; Goltzman D
Biochem Biophys Res Commun; 1990 Dec; 173(3):1058-64. PubMed ID: 2125213
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of cancer cell urokinase plasminogen activator by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradation.
Baker MS; Bleakley P; Woodrow GC; Doe WF
Cancer Res; 1990 Aug; 50(15):4676-84. PubMed ID: 2114945
[TBL] [Abstract][Full Text] [Related]
26. Maximum effect of urokinase plasminogen activator inhibitors in the control of invasion and metastasis of rat mammary cancer.
Evans DM; Sloan-Stakleff KD
Invasion Metastasis; 1998-1999; 18(5-6):252-60. PubMed ID: 10729770
[TBL] [Abstract][Full Text] [Related]
27. Receptor-bound uPA is reversibly protected from inhibition by low molecular weight inhibitors.
Dyer KD; Linz-Mcgillem LA; Alliegro MA; Alliegro MC
Cell Biol Int; 2002; 26(4):327-35. PubMed ID: 11991662
[TBL] [Abstract][Full Text] [Related]
28. Screening of 5- and 6-Substituted Amiloride Libraries Identifies Dual-uPA/NHE1 Active and Single Target-Selective Inhibitors.
Buckley BJ; Kumar A; Aboelela A; Bujaroski RS; Li X; Majed H; Fliegel L; Ranson M; Kelso MJ
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33804289
[TBL] [Abstract][Full Text] [Related]
29. Effects of N-(4-hydroxyphenyl) retinamide on urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in prostate adenocarcinoma cell lines.
Tanabe T
Hiroshima J Med Sci; 2000 Mar; 49(1):67-72. PubMed ID: 10824459
[TBL] [Abstract][Full Text] [Related]
30. Binding site of amiloride to urokinase plasminogen activator depends on species.
Jankun J; Skrzypczak-Jankun E
Int J Mol Med; 2001 Oct; 8(4):365-71. PubMed ID: 11562773
[TBL] [Abstract][Full Text] [Related]
31. The expression and localization of urokinase-type plasminogen activator and its type 1 inhibitor are regulated by retinoic acid and fibroblast growth factor in human teratocarcinoma cells.
Tienari J; Alanko T; Lehtonen E; Saksela O
Cell Regul; 1991 Apr; 2(4):285-97. PubMed ID: 1905574
[TBL] [Abstract][Full Text] [Related]
32. Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.
Merchan JR; Tang J; Hu G; Lin Y; Mutter W; Tong C; Karumanchi SA; Russell SJ; Sukhatme VP
J Natl Cancer Inst; 2006 Jun; 98(11):756-64. PubMed ID: 16757700
[TBL] [Abstract][Full Text] [Related]
33. Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo.
Achbarou A; Kaiser S; Tremblay G; Ste-Marie LG; Brodt P; Goltzman D; Rabbani SA
Cancer Res; 1994 May; 54(9):2372-7. PubMed ID: 8162583
[TBL] [Abstract][Full Text] [Related]
34. Enhancement of the expression of urokinase-type plasminogen activator from PC-3 human prostate cancer cells by thrombin.
Yoshida E; Verrusio EN; Mihara H; Oh D; Kwaan HC
Cancer Res; 1994 Jun; 54(12):3300-4. PubMed ID: 8205553
[TBL] [Abstract][Full Text] [Related]
35. Plasminogen activator activity in bone metastases of prostatic carcinomas as compared to primary tumors.
Kirchheimer JC; Pflüger H; Ritschl P; Hienert G; Binder BR
Invasion Metastasis; 1985; 5(6):344-55. PubMed ID: 4066206
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of urokinase by 4-substituted benzo[b]thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor.
Towle MJ; Lee A; Maduakor EC; Schwartz CE; Bridges AJ; Littlefield BA
Cancer Res; 1993 Jun; 53(11):2553-9. PubMed ID: 8495419
[TBL] [Abstract][Full Text] [Related]
37. Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor.
Cubellis MV; Andreasen P; Ragno P; Mayer M; Danø K; Blasi F
Proc Natl Acad Sci U S A; 1989 Jul; 86(13):4828-32. PubMed ID: 2544876
[TBL] [Abstract][Full Text] [Related]
38. Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans.
Grøndahl-Hansen J; Ralfkiaer E; Kirkeby LT; Kristensen P; Lund LR; Danø K
Am J Pathol; 1991 Jan; 138(1):111-7. PubMed ID: 1702928
[TBL] [Abstract][Full Text] [Related]
39. Production of plasminogen activators (PAs) in bovine cumulus-oocyte complexes during maturation in vitro: effects of epidermal growth factor on production of PAs in oocytes and cumulus cells.
Park KW; Choi SH; Song XX; Funahashi H; Niwa K
Biol Reprod; 1999 Jul; 61(1):298-304. PubMed ID: 10377062
[TBL] [Abstract][Full Text] [Related]
40. Ethyl isopropyl amiloride inhibits smooth muscle cell proliferation and migration by inducing apoptosis and antagonizing urokinase plasminogen activator activity.
Chen YX; O'Brien ER
Can J Physiol Pharmacol; 2003 Jul; 81(7):730-9. PubMed ID: 12897821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]